![LONQUEX 10 MG/ML SOLUÇÃO INJETÁVEL COM 1 SERINGA PREENCHIDA DE 0,6 ML - LIPEGFILGRASTIM - TEVA (REFRIGERADO) - Ative Medicamentos LONQUEX 10 MG/ML SOLUÇÃO INJETÁVEL COM 1 SERINGA PREENCHIDA DE 0,6 ML - LIPEGFILGRASTIM - TEVA (REFRIGERADO) - Ative Medicamentos](https://images.tcdn.com.br/img/img_prod/894000/180_neulastim_6_mg_solucao_injetavel_com_1_seringa_preenchida_de_0_6_ml_pegfilgrastim_amgen_refrigerado_227_1_fbcf88578a3ed54fb0b8faa2ca0e473f.png)
LONQUEX 10 MG/ML SOLUÇÃO INJETÁVEL COM 1 SERINGA PREENCHIDA DE 0,6 ML - LIPEGFILGRASTIM - TEVA (REFRIGERADO) - Ative Medicamentos
![PDF) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events PDF) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events](https://i1.rgstatic.net/publication/317614780_Meta-analysis_and_indirect_treatment_comparison_of_lipegfilgrastim_with_pegfilgrastim_and_filgrastim_for_the_reduction_of_chemotherapy-induced_neutropenia-related_events/links/5a207e6f4585158865c4f924/largepreview.png)
PDF) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe,Supportive Care in Cancer - X-MOL
![Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. | New Drug Approvals Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. | New Drug Approvals](http://images.chemnet.com/service/drug_dict/098/11098_1.jpg)
Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. | New Drug Approvals
Teva's Lonquex®(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropeni
![Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland](https://www.archivesofmedicalscience.com/f/pictures/140623_bf70d.jpg)